Cargando…
Combinatory Treatment with Oseltamivir and Itraconazole Targeting Both Virus and Host Factors in Influenza A Virus Infection
Influenza virus infections and their associated morbidity and mortality are a major threat to global health. Vaccination is an effective influenza prevention measure; however, the effectiveness is challenged by the rapid changes in the influenza virus genome leading to viral adaptation. Emerging vir...
Autores principales: | Schloer, Sebastian, Goretzko, Jonas, Pleschka, Stephan, Ludwig, Stephan, Rescher, Ursula |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412427/ https://www.ncbi.nlm.nih.gov/pubmed/32610711 http://dx.doi.org/10.3390/v12070703 |
Ejemplares similares
-
The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo
por: Schloer, Sebastian, et al.
Publicado: (2019) -
Pharmacologically induced endolysosomal cholesterol imbalance through clinically licensed drugs itraconazole and fluoxetine impairs Ebola virus infection in vitro
por: Kummer, Susann, et al.
Publicado: (2022) -
Repurposing Antifungals for Host-Directed Antiviral Therapy?
por: Schloer, Sebastian, et al.
Publicado: (2022) -
Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS‐CoV‐2 infection in vitro
por: Schloer, Sebastian, et al.
Publicado: (2021) -
Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine
por: Schloer, Sebastian, et al.
Publicado: (2020)